Our board of directors recognized that there was a potential for creating significant value for
shareholders by continuing operations, but on balance our board of directors concluded that the risks of a
negative outcome, either due to failure of our research and development efforts to
yield a successful outcome, or the failure to obtain necessary financing even with positive clinical trial data, and the resulting lower liquidation value in the future, outweighed the potential value to
shareholders from continuing operations.